---
canonical_name: PNC-27
alternate_names: PNC27, PNC 27, p53(15)Ant
canonical_topic: PNC-27 for Health & Longevity
short_topic_lc: pnc_27
creation_date: 2026-1005-1006
creator_ai_fullname: Opus 5.5
ep_keywords: Peptides, Anticancer Peptides, p53-Derived Peptides, Cell-Penetrating Peptides, CPPs, HDM2 Targeting Peptides
---

# PNC-27 for Health & Longevity

<section id="top" markdown="1"></section>  
Evidence Review created on 10/05/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5

**Also known as:** PNC27, PNC 27, p53(15)Ant


## Motivation

<!-- This section was written only after all other sections of the document were completed, so that it reflects the full scope of the topic. -->

PNC-27 is a lab-made peptide, a short chain of 32 amino acids. It joins a fragment of a well-known tumor-suppressing protein to a segment that helps it cross cell membranes. The idea is that it latches onto a protein some cancer cells display on their surface and punches holes in them, while healthy cells lack that surface protein. That design is the main reason it draws interest.

University researchers in New York created the peptide in the early 2000s. It has never been approved as a medicine, yet it has been sold online and offered by clinics outside the United States as a cancer treatment, drawing a regulator warning and the criminal prosecution of one seller. It sits at the edge of the growing interest in experimental peptides among health-minded adults.

This review examines the laboratory, animal and human evidence on PNC-27: what it might do against cancer, which harms have been reported or are plausible, how it is obtained and used, and how far the evidence reaches for people weighing it within a longevity-focused health strategy.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists in-depth sources that discuss PNC-27 directly, from its developers, independent laboratories and the only published human case.

<!-- Search statement: Real-time web searches (WebSearch) were run on 2026-10-02/03 for "PNC-27" combined with peptide, cancer, case report, clinic, blog, podcast and interview. Each priority expert was checked twice: (1) web search "<expert> PNC-27" for Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension and Lifespan.io, all returning no content by these experts on PNC-27; (2) on-site search: peterattiamd.com/?s=PNC-27 ("Nothing Found"), chriskresser.com/?s=PNC-27 ("no search results"), lifespan.io/?s=PNC-27 ("No Articles Found"), hubermanlab.com search-results?q=PNC-27 (only unrelated timestamps, e.g., BPC-157, NMN), foundmyfitness.com/search?q=PNC-27 (only unrelated episodes on protein, sauna, exercise), lifeextension.com/search?q=PNC-27 (d-browser "Access Denied"; d-proxy-2 returned only the generic search page with no PNC-27 article). PubMed (28 records for PNC-27/PNC27/PNC-28) and Europe PMC were screened for narrative reviews and primary research. Candidates rejected: Richard Feinman's Substack post "The PNC-27 Story" (same institution, SUNY Downstate, as the selected developers' review; one item per organization), Bowne et al. 2007 and Pincus et al. 2011 reviews (same developer group), peptide wikis and vendor pages (excluded type), Healio/Pharmacy Times/CURE news items (news reports, not in-depth discussion). -->

- [Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells](https://pubmed.ncbi.nlm.nih.gov/38927351/) - Pincus et al., 2024

  The developers' narrative review of how PNC-27 and its shorter analogue PNC-28 open pores in cancer-cell membranes. Authors include named inventors on PNC-27 patents and a co-author affiliated with NomoCan, a private drug company.

- [Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia](https://pubmed.ncbi.nlm.nih.gov/31337857/) - Wang et al., 2020

  An independent City of Hope study in leukemia (blood cancer) cells and mice; explains HDM2 (human double minute 2, a protein that tags the tumor-suppressor protein p53 for destruction) as the target.

- [Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides](https://pubmed.ncbi.nlm.nih.gov/20484051/) - Yang et al., 2010

  An independent laboratory study that used PNC-27 as its model and found weaker cancer selectivity than its developers report, crediting the penetratin (cell-entry) segment.

- [Experimental PNC-27 Therapy and Massive GI Hemorrhage: A Complication or Coincidence?](https://journals.lww.com/ajg/fulltext/00000434-201710001-01880~experimental-pnc-27-therapy-and-massive-gi-hemorrhage-a) - Aguon et al., 2017

  The only published human report: a woman with end-stage cervical cancer bled massively from the GI (gastrointestinal) tract two days after a PNC-27 infusion in Mexico.

Only four items qualified. No blog post, podcast, lecture or expert commentary discussing PNC-27 in depth was found outside the developers' own institution, which is already represented, so the list was not padded.

None of the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension, Lifespan.io) has published content on PNC-27; web searches and searches of each expert's own site returned nothing relevant, likely because PNC-27 is an unapproved, laboratory-stage cancer peptide rather than a longevity supplement.


## Grokipedia

<!-- Search statement: Tier 1 d-browser loaded grokipedia.com/search?q=PNC-27 (1,940 results, all unrelated: PNC Park, PNC Financial Services, PNC rapper, PNC Tower, etc.) and grokipedia.com/search?q=PNC-27%20peptide (only "Peptide", "Peptide YY" and PNC buildings). d-browser on grokipedia.com/page/PNC-27 returned "Article Not Found". Tier 2 d-fetch on grokipedia.com/page/PNC27 returned HTTP 404. Search results were obtained at tier 1, so no further tiers were needed. -->

No Grokipedia article on PNC-27 was found.


## Examine

<!-- Search statement: Tier 1 d-browser on examine.com/search/?q=PNC-27 returned a "Vercel Security Checkpoint" bot wall. Tier 2 d-fetch returned HTTP 429 (rate limited). Tier 3 d-proxy-1 (browser) loaded the genuine search page: "Sorry, there are no search results for PNC-27." Tier 4 was not needed. -->

No Examine article on PNC-27 was found. Examine.com does not typically cover unapproved investigational drugs.


## ConsumerLab

<!-- Search statement: Tier 1 d-browser loaded consumerlab.com/search/?q=PNC-27 ("Showing Results for PNC 27"). Results matched only the number "27" in unrelated items (e.g., "Avoiding Counterfeits ... 27 brands", "Vitamin C ... 27 products", "Dark Chocolate & Cocoa Review ... 27 products"); no product review, warning or answer about PNC-27. No further tiers were needed. -->

No ConsumerLab article on PNC-27 was found. ConsumerLab does not typically cover unapproved investigational drugs.


## Systematic Reviews

<!-- Search statement: PubMed searched on 2026-10-03 with (PNC-27 OR PNC27 OR "PNC-28" OR "membrane HDM2" OR "membrane-bound HDM-2") AND (systematic review OR meta-analysis): 0 results. A broader PubMed search for PNC-27/PNC27/PNC-28 returned 28 records, none of them a systematic review or meta-analysis (publication types: journal article, narrative review). Europe PMC search likewise returned no systematic review of PNC-27. -->

No systematic reviews or meta-analyses for PNC-27 were found on PubMed as of October 3, 2026.

Neither the claimed anticancer effect nor the principal risks (bleeding, contamination, forgoing proven treatment) are represented by any systematic review or meta-analysis.


## Mechanism of Action

PNC-27 is a 32-amino-acid peptide. Its first 15 amino acids copy residues 12–26 of p53, the stretch p53 uses to bind HDM-2 (HDM2 or MDM2 in some papers); its last 17 are penetratin, a cell-entry segment from a fruit-fly protein ([Kanovsky 2001](https://pubmed.ncbi.nlm.nih.gov/11606716/), [Do 2003](https://pubmed.ncbi.nlm.nih.gov/12629507/)).

- **Primary target:** HDM-2 normally sits inside cells, but cancer cells, and few normal cells, also carry it on their outer membrane ([Sarafraz-Yazdi 2010](https://pubmed.ncbi.nlm.nih.gov/20080680/)).
- **Pore formation:** PNC-27 binds membrane HDM-2 in 1:1 complexes proposed to line holes in the membrane; cell contents leak out, an uncontrolled cell death called necrosis ([Sarafraz-Yazdi 2022](https://pubmed.ncbi.nlm.nih.gov/35625682/)). Leukemia cells released LDH (lactate dehydrogenase, an enzyme that escapes damaged cells) within 4 hours ([Thadi 2020](https://pubmed.ncbi.nlm.nih.gov/32878773/)).
- **Independent of the cancer's own p53:** Killing occurs whether the cell's p53 is normal, mutated or absent ([Kanovsky 2001](https://pubmed.ncbi.nlm.nih.gov/11606716/)).
- **Competing explanations:** An independent leukemia group found PNC-27 also drives breakdown of E-cadherin (a cell-adhesion protein) ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)). Another credited selectivity partly to penetratin binding sugar chains abundant on tumor cells and measured only two-to-threefold selectivity ([Yang 2010](https://pubmed.ncbi.nlm.nih.gov/20484051/)). The developers also report damage to mitochondria (the cell's energy producers) ([Krzesaj 2024](https://pubmed.ncbi.nlm.nih.gov/38802154/)).
- **Pharmacology:** No pharmacokinetic study (measuring how the body absorbs and clears a drug) exists, so half-life, tissue distribution and blood levels are unknown. As an unmodified peptide it should be broken down by protease enzymes into amino acids rather than by CYP (cytochrome P450 liver enzymes); normal cells degraded it soon after contact ([Sookraj 2010](https://pubmed.ncbi.nlm.nih.gov/20182728/)).


## Historical Context & Evolution

- **Original purpose:** Pathologist Matthew Pincus and colleagues at the State University of New York Downstate Medical Center designed p53-derived peptides by computer modeling, aiming to block HDM-2 and restore p53's tumor-suppressing activity ([Kanovsky 2001](https://pubmed.ncbi.nlm.nih.gov/11606716/)).
- **Unexpected finding:** The peptides killed cancer cells by necrosis rather than the programmed cell death p53 normally triggers ([Do 2003](https://pubmed.ncbi.nlm.nih.gov/12629507/)), and the shorter analogue PNC-28 destroyed pancreatic tumors in mice ([Michl 2006](https://pubmed.ncbi.nlm.nih.gov/16688716/)). The membrane-HDM-2 target was described in 2010 ([Sarafraz-Yazdi 2010](https://pubmed.ncbi.nlm.nih.gov/20080680/)), and the inventors patented the peptides ([US patent 8,822,419](https://patents.google.com/patent/US8822419B2/en)).
- **Route to self-use:** Claims of broad cancer killing without harm to normal cells led sellers to market PNC-27 online as a non-toxic cancer cure, and at least one patient received an infusion in Mexico, without any human trial ([Aguon 2017](https://journals.lww.com/ajg/fulltext/00000434-201710001-01880~experimental-pnc-27-therapy-and-massive-gi-hemorrhage-a)). In January 2017 the US Food and Drug Administration (FDA) warned against it after finding bacteria in a sample (reported by [Healio, 2017](https://www.healio.com/news/hematology-oncology/20170112/fda-warns-against-use-of-pnc27-for-cancer-treatment); the FDA notice is no longer online). In 2021 a seller who made suppositories in his kitchen was sentenced to 30 months in prison ([US Department of Justice, 2021](https://www.justice.gov/usao-ndal/pr/birmingham-man-sentenced-making-unapproved-drug-products)).
- **How opinion has shifted:** An independent group confirmed selective killing of leukemia cells in mice ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)), while another laboratory measured weaker selectivity ([Yang 2010](https://pubmed.ncbi.nlm.nih.gov/20484051/)). Both findings come from laboratory and animal work, so whether PNC-27 helps people remains an open question.


## Expected Benefits

<!-- Search statement: Before writing, the complete benefit profile was searched in PubMed (PNC-27 OR PNC27 OR PNC-28: 28 records, all fetched and screened), Europe PMC ("PNC-27" AND patient/case: 44 hits), ClinicalTrials.gov (no registered study of PNC-27) and the web (clinic and vendor claims, case reports, expert commentary). Studies of any design reporting no effect or the opposite effect were sought specifically: none reported absent anticancer activity, but Yang et al. 2010 reported only two-to-threefold selectivity for tumor over normal cells, contradicting the developers' claim of no effect on normal cells. No human efficacy data (trial, cohort, case series or case report of benefit) exist. -->

### High 🟩 🟩 🟩

No benefit reaches High: no human trial of PNC-27 exists; all evidence comes from cell-culture assays and mouse tumor models.

### Medium 🟩 🟩

No benefit reaches Medium: no controlled human study or observational cohort of PNC-27 users has been published; all evidence is laboratory or animal work.

### Low 🟩

### Speculative 🟨

#### Anticancer Activity in Laboratory and Animal Models ⚠️ Conflicted

PNC-27 selectively killed cultured cancer cells ([Do 2003](https://pubmed.ncbi.nlm.nih.gov/12629507/)) and extended leukemic mouse survival ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)). Independent testing found only 2–3-fold selectivity ([Yang 2010](https://pubmed.ncbi.nlm.nih.gov/20484051/)). Laboratory and animal data only. Net: selectivity real but likely partial.

#### Strengthening the Effect of Chemotherapy

In mice with ovarian cancer, adding PNC-27 to paclitaxel (a standard chemotherapy) slowed tumor growth more than paclitaxel alone, and cells surviving paclitaxel became more susceptible ([Alagkiozidis 2017](https://pubmed.ncbi.nlm.nih.gov/28667027/)). Laboratory and animal data only.

#### Cancer Prevention in Healthy Adults

Developers suggest early cancer cells may already carry the membrane target ([Davitt 2014](https://pubmed.ncbi.nlm.nih.gov/25117093/)), implying possible preventive use. No study in animals or people has tested prevention; the idea is purely mechanistic.


## Benefit-Modifying Factors

- **Genetic factors:** The tumor's own p53 status does not change laboratory killing ([Kanovsky 2001](https://pubmed.ncbi.nlm.nih.gov/11606716/)). No inherited variants in the person taking PNC-27 have been studied for effects on benefit.
- **Baseline biomarkers:** Killing tracked the amount of HDM-2 on the tumor-cell surface ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/), [Thadi 2020](https://pubmed.ncbi.nlm.nih.gov/33067207/)); no routine clinical test measures this, so likely responders cannot be identified.
- **Sex differences:** No study has compared response by sex. Laboratory activity spans cancers specific to or common in women, such as ovarian, cervical and breast cancer.
- **Pre-existing conditions:** Cancer type matters. Acute myeloid leukemia cells carried the target, while acute lymphoblastic leukemia (a different blood cancer) cell lines did not ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)). People without cancer have no known target.
- **Age:** No age-specific data exist. Cancer incidence rises with age, so older adults are more likely to carry target-bearing tumors, but no evidence shows they respond differently.


## Potential Risks & Side Effects

<!-- Search statement: Before writing, a drug-reference search was performed: PNC-27 has no prescribing information and no drugs.com, Mayo Clinic or MedlinePlus monograph (web search returned none; it is an unapproved product). FDA sources were checked: the 2017 warning page (fda.gov/Drugs/DrugSafety/ucm536094.htm) and its modern equivalent returned HTTP 404, fda.gov search was blocked by an abuse-detection page, and the FDA criminal-investigation press release URL returned "Page Not Found"; the same event is documented on justice.gov. PubMed was searched for (PNC-27 OR PNC27) AND (pharmacokinetics OR drug interaction OR toxicity OR safety): 4 records, none in humans. The web search found one human case (Aguon et al., American Journal of Gastroenterology 2017 abstract), not indexed in PubMed. Studies showing no excess or lower risk were sought: Wang et al. 2020 found no blood-count or stem-cell changes in healthy mice at 100 mg/kg daily; no human study measured harm. Observational data on alternative cancer treatments in general (Johnson et al. 2018) were included for the opportunity-cost risk. -->

### High 🟥 🟥 🟥

No risk reaches High: the human harm data are a single case report and an observational study of alternative cancer treatments in general, not trials of PNC-27.

### Medium 🟥 🟥

No risk reaches Medium: no controlled study, cohort or case series of PNC-27 users exists; the human evidence is one case report plus indirect data.

### Low 🟥

#### Severe Gastrointestinal Bleeding

A 46-year-old woman with end-stage metastatic cervical cancer vomited large amounts of blood two days after a PNC-27 infusion in Mexico and died ([Aguon 2017](https://journals.lww.com/ajg/fulltext/00000434-201710001-01880~experimental-pnc-27-therapy-and-massive-gi-hemorrhage-a)). Endoscopy found a 2 cm stomach ulcer, a possible independent cause; causation is unproven. Membrane-pore damage ([Sarafraz-Yazdi 2022](https://pubmed.ncbi.nlm.nih.gov/35625682/)) is an untested mechanism. Single case report.

**Magnitude:** Not quantified in available studies. Only one case report exists, with no comparison group, so no rate can be given.

#### Forgoing or Delaying Effective Cancer Treatment

PNC-27 has been marketed and sold as a cancer treatment ([US Department of Justice, 2021](https://www.justice.gov/usao-ndal/pr/birmingham-man-sentenced-making-unapproved-drug-products)). In a US national cancer database, patients using alternative medicine instead of standard treatment had higher mortality ([Johnson 2018](https://pubmed.ncbi.nlm.nih.gov/28922780/)). Indirect: alternative medicine in general was studied, not PNC-27.

**Magnitude:** Alternative medicine alone versus standard treatment in 840 matched patients with non-metastatic breast, prostate, lung or colorectal cancer: HR (hazard ratio, the relative rate of death over time) 2.50, 95% CI (confidence interval, the range likely to contain the true value) 1.88–3.27; 5-year survival 54.7% versus 78.3%; not specific to PNC-27.

### Speculative 🟨

#### Infection from Contaminated Products

An FDA laboratory found *Variovorax paradoxus* bacteria in a PNC-27 inhalation solution; no infections were reported (reported by [Healio, 2017](https://www.healio.com/news/hematology-oncology/20170112/fda-warns-against-use-of-pnc27-for-cancer-treatment)). Basis: product testing, no human outcome data.

#### Damage to Normal Cells ⚠️ Conflicted

Independent testing found PNC-27 only two-to-threefold more toxic to tumor than normal cells ([Yang 2010](https://pubmed.ncbi.nlm.nih.gov/20484051/)); healthy mice showed no blood-count changes ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)). Laboratory and animal data only. Net: normal-cell harm is plausible but unconfirmed.

#### Tumor Lysis Syndrome

Rapid destruction of large tumors can flood the blood with potassium, phosphate and uric acid (tumor lysis syndrome), straining kidneys and heart. PNC-27 bursts cells ([Sarafraz-Yazdi 2022](https://pubmed.ncbi.nlm.nih.gov/35625682/)), but no case is reported. Mechanistic only.

#### Immune or Allergic Reactions

PNC-27 combines human and fruit-fly sequences, and gray-market products may carry synthesis by-products, either of which could provoke antibodies or allergic reactions. No study has measured this; mechanistic concern only.


## Risk-Modifying Factors

- **Genetic factors:** No inherited variants are known to change PNC-27 risk; no study has examined how inherited genes affect response to it. Inherited bleeding disorders would plausibly worsen the bleeding concern.
- **Baseline biomarkers:** Low platelets, prolonged clotting tests or anemia would magnify any bleeding; high uric acid, potassium or LDH before use signal greater tumor lysis vulnerability (theoretical).
- **Sex differences:** None studied. The only bleeding case was a woman with cervical cancer ([Aguon 2017](https://journals.lww.com/ajg/fulltext/00000434-201710001-01880~experimental-pnc-27-therapy-and-massive-gi-hemorrhage-a)); the FDA named pregnant women among those most at risk from contaminated product ([Healio, 2017](https://www.healio.com/news/hematology-oncology/20170112/fda-warns-against-use-of-pnc27-for-cancer-treatment)).
- **Pre-existing conditions:** Tumors invading the stomach, bowel or major vessels, stomach ulcers, kidney disease and weakened immunity (e.g., during chemotherapy) plausibly raise bleeding, tumor lysis or infection risk.
- **Age:** The FDA named older adults and young children among those most at risk from contaminated product ([Healio, 2017](https://www.healio.com/news/hematology-oncology/20170112/fda-warns-against-use-of-pnc27-for-cancer-treatment)); older adults also have less kidney reserve against tumor lysis.


## Key Interactions & Contraindications

<!-- Search statement: Before writing, PubMed was searched for (PNC-27 OR PNC27) AND (pharmacokinetics OR "drug interaction" OR toxicity OR safety) (4 records, none in humans), plus the full PNC-27/PNC27/PNC-28 record set (28 records) for any co-administration data. No human interaction or pharmacokinetic study exists. Laboratory and animal co-treatment data were found for paclitaxel (Alagkiozidis 2017), ketone bodies, rapamycin and methotrexate (Miller 2023), liposomal doxorubicin as a conjugate (Darban 2017), and bortezomib (Wang 2020). -->

No human interaction or pharmacokinetic study of PNC-27 exists, so every interaction below is inferred from mechanism or laboratory data.

**Prescription drugs:**

- **Anticoagulants (blood thinners: warfarin, apixaban, rivaroxaban) and antiplatelet drugs (drugs that stop platelets clumping: clopidogrel, prasugrel):** Caution (theoretical). Could worsen bleeding like the single reported hemorrhage ([Aguon 2017](https://journals.lww.com/ajg/fulltext/00000434-201710001-01880~experimental-pnc-27-therapy-and-massive-gi-hemorrhage-a)). Mitigation: blood counts and INR (international normalized ratio, a clotting test) before and during use.
- **Corticosteroids (anti-inflammatory steroid hormones: prednisone, dexamethasone):** Caution (theoretical). Raise stomach-bleeding and infection risk, compounding the bleeding and contamination concerns. Mitigation: monitor for black stools, vomiting blood and fever.
- **Chemotherapy (paclitaxel):** Monitor (theoretical in humans). In mice, PNC-27 added to paclitaxel's tumor control ([Alagkiozidis 2017](https://pubmed.ncbi.nlm.nih.gov/28667027/)); combined human toxicity is unknown. Mitigation: disclosure to the treating oncologist and matching blood-count checks.
- **Proteasome inhibitors (drugs blocking the cell's protein-disposal system: bortezomib, carfilzomib):** Caution (theoretical); reduced effect possible. Bortezomib partly reversed PNC-27 killing of leukemia cells in the laboratory ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)).
- **MDM2 inhibitors (experimental drugs occupying HDM-2's p53-binding pocket: idasanutlin, navtemadlin):** Caution (theoretical); reduced effect possible. An antibody blocking that pocket prevented PNC-27 killing ([Krzesaj 2024](https://pubmed.ncbi.nlm.nih.gov/38802154/)).

**Over-the-counter medications:**

- **NSAIDs (non-steroidal anti-inflammatory drugs: aspirin, ibuprofen, naproxen):** Caution (theoretical). They injure the stomach lining and impair platelets, potentially adding to bleeding. Mitigation: acetaminophen (paracetamol) is the usual pain-relief alternative when bleeding risk matters.

**Supplements:**

- **Ketone esters and ketone salts (supplements raising blood ketone bodies, a fuel the liver makes from fat):** Monitor (theoretical in humans); potentiation possible. Ketone bodies lowered the PNC-27 concentration needed to kill cultured cancer cells ([Miller 2023](https://pubmed.ncbi.nlm.nih.gov/37760956/)); effects on toxicity are unknown.
- **Fish oil, vitamin E, ginkgo (*Ginkgo biloba*), high-dose curcumin:** Caution (theoretical). Mild antiplatelet effects could add to bleeding risk. Mitigation: pausing them during use removes the overlap.

**Other interventions:**

- **Surgery and radiotherapy:** Monitor (theoretical). Adding a tissue-destroying peptide around surgery or radiation adds unquantified bleeding and wound risk. Mitigation: informing the surgical or radiation team allows timing adjustments.

**Populations who should avoid PNC-27:**

- People with curable cancers who would use it instead of standard treatment ([Johnson 2018](https://pubmed.ncbi.nlm.nih.gov/28922780/))
- People with active or recent gastrointestinal bleeding, or tumors invading the stomach, bowel or major blood vessels (theoretical, based on [Aguon 2017](https://journals.lww.com/ajg/fulltext/00000434-201710001-01880~experimental-pnc-27-therapy-and-massive-gi-hemorrhage-a))
- People with weakened immune systems, pregnant women, older adults and young children, whom the FDA named as at greatest risk from contaminated product (reported by [Healio, 2017](https://www.healio.com/news/hematology-oncology/20170112/fda-warns-against-use-of-pnc27-for-cancer-treatment))
- Breastfeeding women (no safety data)
- Healthy adults seeking cancer prevention (no data on benefit)

No source gives numeric thresholds for these groups, so they are named as general categories.


## Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

- **Standard cancer care retained:** Using PNC-27, if at all, alongside rather than instead of proven treatment avoids the higher death risk seen when alternative medicine replaces standard care ([Johnson 2018](https://pubmed.ncbi.nlm.nih.gov/28922780/)).
- **Identity, purity and sterility verification:** Batch certificates for identity (mass spectrometry), purity, sterility and endotoxin (bacterial toxin) from an independent laboratory reduce the infection risk shown by the FDA contamination finding.
- **Baseline bleeding-risk screening:** A baseline blood count, platelets and INR, and pausing anticoagulants, NSAIDs and antiplatelet supplements where medically possible, lower the chance of severe gastrointestinal bleeding.
- **Early tumor lysis checks:** People with large or fast-growing tumors benefit from hydration and checks of potassium, phosphate, uric acid, calcium and creatinine 24–72 hours after the first dose, detecting tumor lysis syndrome early.
- **Tumor lysis thresholds:** Two or more of potassium ≥6.0 mmol/L, uric acid ≥8 mg/dL, phosphate ≥4.5 mg/dL or calcium ≤7 mg/dL define laboratory tumor lysis ([Cairo & Bishop 2004](https://pubmed.ncbi.nlm.nih.gov/15384972/)); stopping and urgent care prevent kidney injury.
- **Warning signs for stopping:** Vomiting blood, black stools, fever with chills, or sharply reduced urine prompt stopping and urgent medical assessment, limiting harm from bleeding, infection or tumor lysis.
- **Observed first dose:** A small first dose given under medical observation limits harm if an allergic reaction occurs.


## Therapeutic Protocol

Parameters other than doses that carry no citation (timing, frequency, cycling) reflect common practice; no regimen has been tested in humans.

- **No established human dose:** No dose-finding study has been published; the City of Hope group described pharmacokinetic and dose-schedule studies as ongoing ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)).
- **Doses used in animals:** Healthy mice received 100 mg/kg by daily intraperitoneal (abdominal-cavity) injection for two weeks without blood-count changes ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)); PNC-28 was delivered into the abdominal cavity over two weeks ([Michl 2006](https://pubmed.ncbi.nlm.nih.gov/16688716/)).
- **Community-reported self-use regimens:** A peptide wiki lists 0.2–0.3 mg subcutaneously three times weekly up to 1–5 mg daily ([Peptide Protocol Wiki](https://www.peptideprotocolwiki.com/peptides/pnc27/dosing)); these figures come from no trial and, per kilogram, are over 1,000-fold below the dose healthy mice tolerated.
- **Routes in commerce:** Products have been sold as intravenous solutions, nebulized (inhaled) solutions, and rectal and vaginal suppositories (reported by [Healio, 2017](https://www.healio.com/news/hematology-oncology/20170112/fda-warns-against-use-of-pnc27-for-cancer-treatment)).
- **Competing approaches:** The inventors pursue formal drug development; clinics abroad offer infusions directly; conventional oncology relies on approved therapies. Each approach reflects different evidence standards and risk tolerance; none has human outcome data for PNC-27.
- **Who popularized it:** Inventors Matthew Pincus, Josef Michl and Ehsan Sarafraz-Yazdi developed it ([US patent 8,822,419](https://patents.google.com/patent/US8822419B2/en)); online sellers marketed it for direct use, and a patient was infused in Mexico ([Aguon 2017](https://journals.lww.com/ajg/fulltext/00000434-201710001-01880~experimental-pnc-27-therapy-and-massive-gi-hemorrhage-a)).
- **Time of day:** No data; animal studies dosed once daily without regard to time of day.
- **Half-life:** Not measured in humans or reported in animals. As an unmodified peptide it is exposed to rapid protease breakdown, and in normal cells it was degraded soon after contact ([Sookraj 2010](https://pubmed.ncbi.nlm.nih.gov/20182728/)).
- **Single versus split dosing:** No comparative data; animal regimens used single daily injections ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)).
- **Genetic factors:** No data on how inherited genes affect response guide dosing; the tumor's own p53 status did not affect laboratory killing ([Kanovsky 2001](https://pubmed.ncbi.nlm.nih.gov/11606716/)).
- **Sex differences:** No sex-specific dosing, response or efficacy data exist.
- **Age:** No age-specific data exist; older adults' lower kidney reserve and higher bleeding tendency matter for tumor lysis and hemorrhage risks.
- **Baseline biomarkers:** Laboratory response tracked tumor-surface HDM-2 levels ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)); no validated clinical test predicts response.
- **Pre-existing conditions:** Large tumor burden, kidney disease and bleeding-prone tumors raise risk; people without cancer have no known target for the peptide.


## Discontinuation & Cycling

- **Short-term only:** Every published animal regimen lasted days to weeks ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)); no rationale or data support lifelong use.
- **Withdrawal effects:** None known; no study has examined stopping.
- **Tapering:** Not applicable; direct cell killing gives no reason to expect dependence or rebound.
- **Cycling:** No data on cycling or on whether cancer cells stop displaying surface HDM-2 under repeated exposure.
- **Stopping triggers:** Bleeding, fever, allergic symptoms or laboratory signs of tumor lysis are reasons to stop immediately.


## Sourcing and Quality

- **No approved pharmaceutical source:** PNC-27 is not FDA-approved and has never undergone US clinical trials, so no regulated manufacturer exists ([US Department of Justice, 2021](https://www.justice.gov/usao-ndal/pr/birmingham-man-sentenced-making-unapproved-drug-products)).
- **Research-grade supply:** Chemical suppliers sell it labeled for research only; the convicted US seller bought it from a Chinese supplier while claiming laboratory use ([US Department of Justice, 2021](https://www.justice.gov/usao-ndal/pr/birmingham-man-sentenced-making-unapproved-drug-products)).
- **Contamination record:** The FDA found bacteria in an inhalation product (reported by [Healio, 2017](https://www.healio.com/news/hematology-oncology/20170112/fda-warns-against-use-of-pnc27-for-cancer-treatment)); the convicted seller made suppositories in a non-sterile kitchen.
- **What to look for:** Batch-specific certificates from an independent laboratory showing identity by mass spectrometry, purity by HPLC (high-performance liquid chromatography), sterility and endotoxin testing.
- **Brands and pharmacies:** No reputable brand or compounding pharmacy offering verified pharmaceutical-grade PNC-27 was identified.
- **Formulation and storage:** Supplied as freeze-dried powder for reconstitution; storage frozen and protected from light is advised, with reconstituted solution used within about a week ([Peptide Protocol Wiki](https://www.peptideprotocolwiki.com/peptides/pnc27/dosing)).


## Practical Considerations

- **Time to effect:** Cultured leukemia cells die within about 4 hours ([Thadi 2020](https://pubmed.ncbi.nlm.nih.gov/32878773/)); in mice, effects emerged over weeks of dosing ([Wang 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)). Time to any effect in people is unknown.
- **Common pitfalls:** Trusting "non-toxic cure" marketing, replacing proven treatment, buying unverified product, and assuming it restores p53 (it kills cells by membrane pores instead).
- **Regulatory status:** Not FDA-approved and never tested in US clinical trials; a US seller was imprisoned for distributing it ([US Department of Justice, 2021](https://www.justice.gov/usao-ndal/pr/birmingham-man-sentenced-making-unapproved-drug-products)). The FDA warned against it in 2017 (reported by [Healio, 2017](https://www.healio.com/news/hematology-oncology/20170112/fda-warns-against-use-of-pnc27-for-cancer-treatment)).
- **Access and cost:** Obtainable only through research-chemical vendors or clinics abroad; prices are unpublished and unstandardized. No insurer covers it, so payer incentives play no identifiable role in its evidence base.
- **Who produces the evidence:** Most studies come from the inventors named on its patents, some with a co-author affiliated with NomoCan, a private drug company; sellers and clinics have direct sales interests.


## Interaction with Foundational Habits

- **Sleep:** None known (no data). No mechanism links PNC-27 to sleep; any night sweats or fever after dosing would point to infection or tumor breakdown rather than a direct sleep effect.
- **Nutrition:** Potentiating in the laboratory only. Ketone bodies, the fuel produced on a ketogenic diet (very low-carbohydrate, high-fat eating), lowered the PNC-27 concentration needed to kill cultured cancer cells ([Miller 2023](https://pubmed.ncbi.nlm.nih.gov/37760956/)); a ketogenic diet with PNC-27 is untested in people. No nutrient depletion is described.
- **Exercise:** None known (no data). Indirectly, if bleeding risk or low platelets are present, contact sports and heavy straining around dosing days add avoidable bleeding risk.
- **Stress management:** None known (no data). No effect on cortisol or stress responses has been studied; no practical adjustment is indicated.


## Monitoring Protocol & Defining Success

Baseline testing before any use establishes bleeding risk, kidney function and tumor-breakdown markers: a complete blood count with platelets, INR, kidney function and electrolytes, uric acid, LDH, and whatever tumor marker and imaging already track the person's cancer.

Ongoing monitoring follows common practice for a tissue-destroying agent: electrolytes, uric acid and creatinine at 24–72 hours after the first dose and at 1 week, then blood counts and chemistries every 2–4 weeks while in use; tumor markers and imaging at the usual oncology intervals, typically every 2–3 months. Success can only be defined by objective tumor change on imaging or markers, compared with the person's own baseline, because symptoms alone cannot separate a drug effect from the natural course of the disease.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Hemoglobin | Men 13.2–16.6 g/dL; women 11.6–15.0 g/dL (standard reference range) | Safety check: a fall signals bleeding | Part of the complete blood count; no fasting needed; cancer itself can lower it, so compare with baseline |
| Platelets | 150–450 ×10⁹/L (standard reference range) | Safety check: low counts raise bleeding risk | Part of the complete blood count; pair with INR |
| INR | 0.8–1.1 (standard reference range) | Safety check: prolonged clotting raises bleeding risk | International normalized ratio, a standardized clotting test; anticoagulants raise it |
| Potassium | 3.5–5.0 mmol/L (standard reference range) | Safety check: a rise signals tumor lysis | ≥6.0 mmol/L is one laboratory tumor lysis criterion ([Cairo & Bishop 2004](https://pubmed.ncbi.nlm.nih.gov/15384972/)); a broken-down sample can falsely raise it |
| Phosphate | 2.5–4.5 mg/dL (standard reference range) | Safety check: a rise signals tumor lysis | ≥4.5 mg/dL in adults is one tumor lysis criterion ([Cairo & Bishop 2004](https://pubmed.ncbi.nlm.nih.gov/15384972/)) |
| Uric acid | 3.5–7.2 mg/dL (standard reference range) | Safety check: a rise signals tumor lysis | ≥8 mg/dL is one tumor lysis criterion ([Cairo & Bishop 2004](https://pubmed.ncbi.nlm.nih.gov/15384972/)) |
| Calcium | 8.6–10.3 mg/dL (standard reference range) | Safety check: a fall signals tumor lysis | ≤7 mg/dL is one tumor lysis criterion ([Cairo & Bishop 2004](https://pubmed.ncbi.nlm.nih.gov/15384972/)); interpret with albumin |
| Creatinine | Men 0.74–1.35 mg/dL; women 0.59–1.04 mg/dL (standard reference range) | Safety check: kidney injury from tumor lysis | Draw with potassium, phosphate, uric acid and calcium |
| LDH | 140–280 U/L (standard reference range) | Expected to change: rises as cells burst; also a tumor lysis safety check | Lactate dehydrogenase; already high in many cancers, so the trend against baseline matters |
| Cancer-specific tumor marker (e.g., CA-125, CEA, PSA) | No established target; track change from the individual's own baseline | Expected to change if the tumor responds | CA-125 (cancer antigen 125, ovarian), CEA (carcinoembryonic antigen, bowel), PSA (prostate-specific antigen); use the same laboratory each time |

Qualitative markers:

- Signs of bleeding: vomiting blood, black or bloody stools, unusual bruising
- Fever, chills or redness at the injection or infusion site, suggesting infection
- Urine output, swelling and muscle cramps, which can reflect tumor lysis
- Energy, appetite and weight
- Tumor-related symptoms such as pain or breathlessness


## Emerging Research

- **No registered human trials:** A ClinicalTrials.gov search in October 2026 found no PNC-27 study, so no ongoing trial exists. A first safety trial showing tolerable dosing would move risk grades onto human data; serious toxicity would largely close the case for self-use.
- **Diagnostic use of the same target:** [Krzesaj et al. 2025](https://pubmed.ncbi.nlm.nih.gov/40750238/) found membrane HDM-2 on cervical cancer but not normal cervical cell lines, stable in alcohol-based cell preservative fluid. Confirmation in patient samples would support, and failure would weaken, the claim that the target is cancer-specific.
- **Targeted drug delivery:** PNC-27 used as a homing tag improved liposomal doxorubicin's tumor control in mice ([Darban et al. 2017](https://pubmed.ncbi.nlm.nih.gov/28565974/)) and was tested on iron-oxide particles for cancer imaging ([Rahmani et al. 2022](https://pubmed.ncbi.nlm.nih.gov/36311203/)).
- **Unresolved mechanism:** Pores lined by PNC-27–HDM-2 complexes ([Sarafraz-Yazdi et al. 2022](https://pubmed.ncbi.nlm.nih.gov/35625682/)), E-cadherin breakdown ([Wang et al. 2020](https://pubmed.ncbi.nlm.nih.gov/31337857/)) and penetratin–sugar binding ([Yang et al. 2010](https://pubmed.ncbi.nlm.nih.gov/20484051/)) compete; independent replication could strengthen or weaken the selectivity claim.
- **Combinations:** Paclitaxel synergy in mice ([Alagkiozidis et al. 2017](https://pubmed.ncbi.nlm.nih.gov/28667027/)) and ketone potentiation in culture ([Miller et al. 2023](https://pubmed.ncbi.nlm.nih.gov/37760956/)) are untested in people; human data could show added benefit or added toxicity.
- **Human safety signal:** Beyond one bleeding case ([Aguon et al. 2017](https://journals.lww.com/ajg/fulltext/00000434-201710001-01880~experimental-pnc-27-therapy-and-massive-gi-hemorrhage-a)), no adverse-event series exists. Systematic outcome reporting from clinics using PNC-27 could either reinforce or dispel the bleeding concern.


## Conclusion

PNC-27 is a lab-made protein fragment designed to latch onto a protein found on the surface of many cancer cells and punch holes in them. In laboratory dishes and in mice it has killed a wide range of cancer cells, slowed tumor growth and lengthened survival, and one independent research team has confirmed part of this work in leukemia. Another independent team found that its preference for cancer cells over normal cells may be weaker than its developers describe.

No study in people has tested whether it treats or prevents cancer, how much of it reaches the body, or how long it lasts there. The human record consists of one report of fatal bleeding after an intravenous infusion, where cause could not be proven, a regulator's discovery of bacteria in a product sample, and a criminal case against a seller who made it in a home kitchen. Products sold today come from outside any regulated system, so their identity and cleanliness are uncertain.

Most of the supporting research comes from the inventors, who are named on patents covering the compound, and from authors linked to a private drug company, giving them a financial stake in favorable findings; sellers and clinics have a direct sales interest. For health-focused adults, the potential of PNC-27 rests on animal and laboratory findings, while its real-world risks include contaminated products, possible serious bleeding and the danger of setting aside proven cancer care.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**